Comparing Risk and Severity of IRRs in Patients Premedicated With Cetirizine vs. Diphenhydramine Prior to Ocrelizumab

Comparing Risk and Severity of IRRs in Patients Premedicated With Cetirizine vs. Diphenhydramine Prior to Ocrelizumab

Publication date: Nov 25, 2019

This 6-month randomized controlled pilot study will determine whether there is some evidence that cetirizine is better tolerated than diphenhydramine without an increase in Infusion-Related Reactions (IRRs) in subjects receiving ocrelizumab(OCR) for multiple sclerosis (MS).

Concepts Keywords
Acetaminophen HIV
Allergy Participation study allergy
Cetirizine Multiple Sclerosis PPMS
Cognitive Untreated hepatitis
Comorbidity Tuberculosis
Contraception Contraception
Depression Premedication
Diphenhydramine Psychoactive drugs
Gram RTT
Hepatitis Monoclonal antibodies
HIV Positive Breakthrough therapy
Immunosuppressive Medication Carboxylic acids
Infection Ethers
Informed Consent Ocrelizumab
Infusion Diphenhydramine
IRR Cetirizine
Lactation Multiple sclerosis
Lymphocyte Premedication
Methylprednisolone OCR
Multiple Sclerosis
OCR
PML
Progressive
Progressive Multifocal Leukoencephalopathy
Prophylactic
Providence Services
Psychiatric Disorder
Sedation
Somatic
Tuberculosis

Semantics

Type Source Name
drug DRUGBANK Cetirizine
drug DRUGBANK Diphenhydramine
drug DRUGBANK Ocrelizumab
drug DRUGBANK Tropicamide
disease MESH multiple sclerosis
disease MESH hepatitis B
pathway KEGG Hepatitis B
disease MESH infection
disease MESH hepatitis C
pathway KEGG Hepatitis C
disease MESH tuberculosis
pathway KEGG Tuberculosis
disease MESH Progressive multifocal leukoencephalopathy
disease MESH depression
disease MESH comorbidity
disease MESH allergy

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *